Use of patient preferences in HTA processes

Learn which role patient preference data can play in HTA processes

No available dates

On location

Danish

2,950 DKK ex VAT

(app. 397 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Patient preferences when using medicine is already part of the approval process for new medicines in FDA and EMA.

At this hot topic seminar, you gain an understanding of how patient involvement and patient preferences can be used to demonstrate the value of pharmaceutical products. You will hear, how a hospital doctor systematically has increased patient adherence through more patient involvement . You will also hear a representative from a pharmaceutical company present how they successfully made use of patient preferences to generate positive patient outcomes for a new innovative medicinal product. Last but least, the chairman of the Danish Medicines Council will present how they regard the use of such data in relation to strengthening a HTA application.


Keywords

  • Patient preferences
  • Patient Advocacy
  • Patient involvement
  • Medical Affairs
  • HTA processes

Save information for later
Read more

Course leader & lecturers

  • Elisabeth Gammelgaard Ludvig
    Course leader
    Owner
    Sundhedsagenda
  • Agathe Le Lay
    Lecturer
    Vice President, Global Head of Value Evidence
    Lundbeck A/S
  • Jacoline Bouvy
    Lecturer
    Technical Director
    National Institute for Health and Care Excellence (NICE)
  • Karina Dahl Steffensen
    Lecturer
    Professor, Cheflæge, Center for Fælles Beslutningstagning
    Sygehus Lillebælt, Syddansk Universitetshospital
  • Jørgen Schøler Kristensen
    Lecturer
    Kst Koncerndirektør
    Medicinrådet
See all

Is this course for you?

Join this seminar if you work in a consultancy or pharmaceutical company within medical affairs, market access, public affairs, sales & marketing, or patient advocacy.

What you will learn


  1. Understand what patient preferences are, and how they can be generated qualitatively and quantitatively.
  2. Learn how The Danish Medicines Council views patient preference data, and how and if it expects to include patient preferences in its future considerations.
  3. Learn how a pharma HQ works with patient preference data in HTA processes.
  4. Understand how Danish HCPs work with patient involvement and patient preferences in joint decision making when choosing treatment type, and how pharma companies can support this work.

What your company will get


  1. An employee who understands patient preferences and how these can be developed.
  2. An employee who understands how patient preferences can be utilised in cross-functional work within a pharma company in drug development, during market access and during launch.

Course information

Literature

Recommended readings:

Metodehaandbog-for-terapiomraader_adlegacy.pdf(medicinraadet.dk) (sections 3 and 4.1.2)

    Prerequisites

    Industry knowledge is an advantage.

    Examination

    There is no examination for this course.

    Course leader

    Elisabeth Gammelgaard Ludvig
    Owner
    Sundhedsagenda

    Lecturers

    Agathe Le Lay
    Vice President, Global Head of Value Evidence
    Lundbeck A/S
    Jacoline Bouvy
    Technical Director
    National Institute for Health and Care Excellence (NICE)
    Karina Dahl Steffensen
    Professor, Cheflæge, Center for Fælles Beslutningstagning
    Sygehus Lillebælt, Syddansk Universitetshospital
    Jørgen Schøler Kristensen
    Kst Koncerndirektør
    Medicinrådet

    You may also be interested in these courses

    Want to know more or need help?

    Contact Client Manager Christina Spangsberg at +45 39 15 09 22